Comprehensive Characterization of Reference Standard Lots of HIV-1 Subtype C Gp120 Proteins for Clinical Trials in Southern African Regions

@inproceedings{Wang2016ComprehensiveCO,
  title={Comprehensive Characterization of Reference Standard Lots of HIV-1 Subtype C Gp120 Proteins for Clinical Trials in Southern African Regions},
  author={Zihao Wang and Clarisse Lorin and Marguerite Koutsoukos and David Franco and Babak Bayat and Ying Zhang and Andrea Carf{\'i} and S Wienand Barnett and Frederick Porter},
  booktitle={Vaccines},
  year={2016}
}
Two HIV-1 subtype C gp120 protein candidates were the selected antigens for several experimental vaccine regimens now under evaluation in HVTN 100 Phase I/II clinical trial aiming to support the start of the HVTN 702 Phase IIb/III trial in southern Africa, which is designed to confirm and extend the partial protection seen against HIV-1 infection in the RV144 Thai trial. Here, we report the comprehensive physicochemical characterization of the gp120 reference materials that are representative… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-7 of 7 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 21 references

GSK Vaccines

C. Zambonelli, A. K. Dey, +7 authors H Liao
2016
View 2 Excerpts

Broadly neutralizing antibodies suppress HIV in the persistent viral reservoir.

Proceedings of the National Academy of Sciences of the United States of America • 2014
View 1 Excerpt

Similar Papers

Loading similar papers…